TrialCompass™ TCL
Back to results
Phase 2RecruitingPriority 3 · Moderate priorityNCT07106723

Clinical Study of the Safety and Efficacy of ASCT Combined With CD7-CART in the Treatment of CD7+ TCL

ClinicalTrials.gov

Plain-language summary

This Phase 2 trial is evaluating ASCT+CD7-CART as a treatment for people newly diagnosed with T-cell lymphoma. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

Who can join (key eligibility)

  • Age 18 Years to 65 Years years
  • Newly diagnosed, not yet treated

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

ASCT+CD7-CART (DRUG): Intravenous infusion of CD7-CART 3 days after ASCT

Drugs / treatments
ASCT+CD7-CART
Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details
TrialCompass — Clinical Trial Summary

Clinical Study of the Safety and Efficacy of ASCT Combined With CD7-CART in the Treatment of CD7+ TCL

NCT07106723

Phase: Phase 2 | Status: Recruiting | Priority: Medium

Plain-language summary

This Phase 2 trial is evaluating ASCT+CD7-CART as a treatment for people newly diagnosed with T-cell lymphoma. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

Who can join

  • Age 18 Years to 65 Years years
  • Newly diagnosed, not yet treated

What's being tested

ASCT+CD7-CART (DRUG): Intravenous infusion of CD7-CART 3 days after ASCT

Drugs / treatments: ASCT+CD7-CART

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, open-label

Enrollment target: 50 patients

Primary endpoint: PFS rate at 1 year after ASCT conbined with CD7-CART; Incidence and Severity of Adverse Events after ASCT conbined with CD7-CART

Ages: 18 Years to 65 Years

Start date: 2025-06-01 | Est. completion: 2030-01-07

Locations

0 US sites · 1 total

Contact

Liang Huang, Dr | huangliang@ihcams.ac.cn | 022-23608359

Sponsor: Institute of Hematology & Blood Diseases Hospital, China (OTHER)

Tags

All T-cell lymphomas · Maintenance · Newly diagnosed

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT07106723

Prepared using TrialCompass (trialcompass.com) on July 4, 2026. For informational purposes only. Always discuss with your healthcare team.